In mice, the combination therapy not only improved the health of aging mice, but also extended their lifespan by around 30 ...

Researchers at the Max Planck Institute for Biology of Aging have discovered that the combination of the two cancer drugs, ...

The combination of two cancer drugs, rapamycin and trametinib, can extend the lifespan of mice by 30%, according to a study ...

The researchers were able to show that Trametinib alone extends the lifespan of mice by 5-10%, while Rapamycin alone ...

The two drugs are already used to treat cancer in humans and were found to reduce chronic inflammation and delay the onset of ...

One type of ovarian cancer looks likely to be a new indication for the MEK inhibitor trametinib (Mekinist), which is already approved in the US for use in melanoma, non–small cell lung cancer ...

The ORR with trametinib was 26%, with 59% having stable disease for at least eight weeks. The median duration of response on trametinib and standard-of-care were 13.6 months and 5.9 months ...

The researchers found that at five years, the percentages of patients who were alive without relapse were 52 and 36 percent for dabrafenib plus trametinib and placebo, respectively (hazard ratio ...

Trametinib (GSK1120212, GlaxoSmithKline Pharmaceuticals) is an orally available, small-molecule, selective inhibitor of MEK1 and MEK2. 12 At doses that appeared to be nontoxic, trametinib ...

Dabrafenib and trametinib are types of targeted cancer drugs. Dabrafenib is also known as Tafinlar. Trametinib is also known as Mekinist. You pronounce dabrafenib as da-bra-fe-nib. And trametinib as ...